Artiva Biotherapeutics halts lead cell‑therapy program and cuts 94% of staff
Artiva Biotherapeutics announced it will stop development of its AlloNK® (AB‑101) program after two fatal Grade 5 safety events and longer‑term data that did not meet its durability threshold. The company will reduce its workforce by roughly 94% and has engaged Leerink Partners to evaluate strategic alternatives, which may include a sale, merger, licensing or liquidation. As of September 30, 2026 the firm held about $319.1 million in cash and liquid assets, according to an unaudited balance sheet.
Why it matters
The shutdown removes the company’s only late‑stage asset, leaving cash as the primary source of value; investors have pushed the share price down about 30% as the market re‑prices the business toward a potential wind‑down scenario.
Key facts
- 1Artiva will discontinue further development of AlloNK® (AB‑101) and will not initiate the planned Phase 3 pivotal trial. stocktitan.net
- 2Two Grade 5 safety events were reported: a fatal leukoencephalopathy case linked to fludarabine toxicity and a second death deemed unrelated to the study treatment. stocktitan.net
- 3The company plans to cut approximately 94% of its workforce. stocktitan.net
- 4Leerink Partners has been hired as financial advisor to explore strategic alternatives. stocktitan.net
- 5Artiva reported cash, cash equivalents and investments of roughly $319.1 million (preliminary, unaudited) as of September 30, 2026. tradingview.com
- 6Shares fell about 30% in pre‑market trading following the announcement. investing.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.